Vinge advised Cantargia on the deal.Cantargia AB (publ) secured a rights offering of approximately SEK 170 million. Cantargia develops antibody based therapies against the target IL1RAP….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
